«
Purchase applications decreased 4 percent over the week, and were 21 percent lower than a year ago.
Not exact matches
These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and
decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP
purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug
applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).
Despite interest rates holding at their lowest level in two months, mortgage
applications to
purchase a home fell 2 percent for the week, the first
decrease in a month.
CONTACT Ali Ahmad
[email protected] (202) 557 - 2727 WASHINGTON, D.C. (June 11, 2015)- The Mortgage Bankers Association (MBA) Builder
Application Survey (BAS) data for May 2015 shows mortgage
applications for new home
purchases decreased by 9 percent relative to the previous month.
CONTACT Ali Ahmad
[email protected] (202) 557 - 2727 WASHINGTON, D.C. (August 13, 2015)- The Mortgage Bankers Association (MBA) Builder
Application Survey (BAS) data for July 2015 shows mortgage
applications for new home
purchases decreased by 4 percent relative to the previous month.
Mortgage
applications for new home
purchases in the U.S.
decreased 2.6 percent compared to March 2017.
The February 2018
decrease in
applications for both conventional and government
purchase mortgages as well as any changes in credit standards, a metric of mortgage supply, will be closely tracked for evidence of a longer declining trend.
The lease, if it has fewer than 10 payments left on it at the time of your
application, would not be factored into your debt to income ratio (this would increase your
purchasing capacity by
decreasing your debt to income ratio).
Additionally, when looking at the adjusted index of mortgage
application activity, which includes refinancing and
purchase applications, there was an overall
decrease of 2.6 percent in the week ended July 12.
Purchase applications rose by 1.0 percent, but refinancing
applications continued to decline and are now at a 2 - year low after
decreasing by 4.0 percent.
Overall, mortgage
applications slightly grew 2.7 % from one week earlier, with the seasonally adjusted
purchase index
decreasing 2 % from one week earlier.
Applications to
purchase a home
decreased 6 percent last...
Mortgage
applications for new home
purchases in the U.S.
decreased 2.6 percent compared to March 2017.
Demand for mortgages on
purchases of homes rose for the third consecutive week last week while
applications for refinancing
decreased, according to The Mortgage Bankers Association's (MBA's) seasonally adjusted index of overall mortgage
application activity.
In February 2012, United States
purchase application volume increased by 18.0 percent from January 2012 and
decreased 2.0 percent from the same time last year.